BRIM Biotechnology, Inc. (TPEX: 6885)

Market Cap	5.00B
Revenue (ttm)	111.00K
Net Income (ttm)	-466.63M
Shares Out	115.75M
EPS (ttm)	-4.10
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	626,312
Open	42.15
Previous Close	42.30
Day's Range	41.95 - 43.30
52-Week Range	24.60 - 80.50
Beta	1.17
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 13, 2024

About BRIM Biotechnology

BRIM Biotechnology, Inc., a clinical-stage company, engages in the development of novel regenerative therapies to combat and cure ophthalmology and degenerative joint diseases. The company’s lead product candidate is BRM 421, a topical ophthalmic solution for patients with moderate-to-severe dry eye syndrome that has completed a phase 2 clinical trial in the United States. It is also developing BRM 423 to treat severe corneal damage, which is in phase 1 clinical trial; BRM 424 for the treatment of neurotrophic keratitis, which is in phase 1 cli...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2013
• Country: Taiwan
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 6885

Financial Performance

In 2023, BRIM Biotechnology's revenue was 90,000, a decrease of -82.89% compared to the previous year's 526,000. Losses were -688.02 million, 150.8% more than in 2022.